Pharmacogenetics of hypertension treatment: A structured review

Pharmacogenetics

Volumn 13, Issue 12, 2003, Pages 705-713

  Koopmans, Richard P ^a,c   Insel, Paul A ^b   Michel, Martin C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

blocker; Angiotensin converting enzyme inhibitor; Diuretic; Genetics; Hypertension treatment

Indexed keywords

AMILORIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IMIDAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; QUINAPRIL;

BLOOD PRESSURE; DRUG METABOLISM; GENE DELETION; GENE INSERTION; GENE INTERACTION; GENE TARGETING; GENOTYPE; HUMAN; HYPERTENSION; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOTENSINOGEN; CALMODULIN-BINDING PROTEINS; GTP-BINDING PROTEINS; HUMANS; HYPERTENSION; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ANGIOTENSIN;

INSERTION SEQUENCES;

EID: 1342295634     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200312000-00001     Document Type: Short Survey

References (55)

1. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277:739-745.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
3. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85:251-255.
4. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26:60-69.
5. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.
6. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914-921.
7. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290:199-206.
8. Preston RA, Materson BJ, Reda DJ, Williams DW, Hamburger RJ, Cushman WC, Anderson RJ. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. JAMA 1998; 280:1168-1172.
9. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001; 19:1-11.
10. Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics 2003; 4:53-65.
11. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
12. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104:545-556.
13. Michel MC, Insel PA. Receptor gene polymorphisms: lessons on functional relevance from the beta(1)-adrenoceptor. Br J Pharmacol 2003; 138:279-282.
14. Siffert W. Effects of the G protein beta 3-subunit gene C825T polymorphism: should hypotheses regarding the molecular mechanisms underlying enhanced G protein activation be revised? Focus on 'A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels'. Physiol Genom 2003; 13:81-84.
15. Li X, Du Y, Du Y, Huang X. Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Casdiovasc Pharmacol Ther 2003; 8:25-30.
16. Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T. Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998; 11:174-183.
17. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, Cusi D. ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 2003; 41:398-403.
18. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14:427-432.
19. Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, et al. Angiotensin-converting enzyme gene polymorphism determines the anti-proteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 1998; 21:66-69.
20. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001; 19:1783-1787.
21. Ohmichi N, Iwai N, Uchida Y, Shichiri G, Nakamura Y, Kinoshita M. Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10:951-955.
22. O'Toole L, Stewart M, Padfield P, Channer K. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998; 32:988-994.
23. Suwelack B, Kempkes-Koch M, Kobelt V, Hillebrand U, Matzkies F, Gerhardt U, Hohage H. Impact of ACE polymorphism on renal allograft function, blood pressure, and proteinuria under ACE inhibition. Transplant Proc 2002; 34:1763-1766.
24. Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996; 14:259-262.
25. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13:1602-1609.
26. Katsuya T, Iwashima Y, Sugimoto K, Motone M, Asai T, Fukuda M, et al. Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 2001; 24:463-467.
27. Nakano Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G, Kambe M. Angiotensin I-converting enzyme gene polymorphism and acute response to captopril in essential hypertension. Am J Hypertens 1997; 10:1064-1068.
28. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62:1718-1723.
29. Todd GP, Chadwick IG, Higgins KS, Yeo WW, Jackson PR, Ramsay LE. Relation between changes in blood pressure and serum ACE activity after a single dose of enalapril and ACE genotype in healthy subjects. Br J Clin Pharmacol 1995; 39:131-134.
30. Miller JA, Thai K, Scholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999; 56:2173-2180.
31. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445:151-152.
32. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349:1353-1357.
33. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34:649-654.
34. Jia H, Hingorani AD, Sharma P, Hopper R, Dickerson C, Trutwein D, et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34:8-14.
35. Nürnberger J, Dammer S, Mitchell A, Siffert W, Wenzel RR, Gössl M, et al. Effect of C825T polymorphism of the G protein beta3 subunit on the systolic blood pressure lowering effect of clonidine in young, healthy males. Clin Pharmacol Ther 2003; 74:53-60.
36. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37:739-743.
37. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. β1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
38. O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects. Clin Sci (Lond) 2000; 99:233-238.
39. Sofowora GG, Dishy V, Muszkat M, Xie HG, Kim RB, Harris PA, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73:366-371.
40. Baker EH, Duggal A, Dong Y, Ireson NJ, Wood M, Markandu ND, MacGregor GA. Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension 2002; 40:13-17.
41. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002; 20:2089-2093.
42. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003; 13:7-17.
43. Staessen JA, Ginocchio G, Wang JG, Saavedra AP, Soubrier F, Vlietinck R, Fagard R. Genetic variability in the renin-angiotensin system: prevalence of alleles and genotypes. J Cardiovasc Risk 1997; 4:401-422.
44. Ferrari P, Bianchi G. Genetic mapping and tailored antihypertensive therapy. Cardiovasc Drugs Ther 2000; 14:387-95.
45. Ruiz-Velasco V, Ikeda SR. A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. Physiol Genom 2003; 13:85-95.
46. Johnson JA, Terra SG. Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharm Res 2002; 19:1779-1787.
47. Haluschka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73:122-130.
48. Hyndman ME, Parsons HG, Verma S, Bridge PJ, Edworthy S, Jones C, et al. The T-786>C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension 2002; 39:919-922.
49. Jachymova M, Horky K, Bultas J, Kozich V, Jindra A, Peleska J, Martasek P. Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem Biophys Res Commun 2001; 284:426-430.
50. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF. Oxidation phenotype - a major determinant of metoprolol metabolism and response. N Engl J Med 1982; 307:1558-1560.
51. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4:45-61.
52. Jones A, Montgomery H. The Gly389Arg beta-1 adrenoceptor polymorphism and cardiovascular disease: time for a rethink in the funding of genetic studies? Eur Heart J 2002; 23:1071-1074.
53. Ranade K, Hinds D, Hsiung CA, Chuang LM, Chang MS, Chen YT, et al. A genome scan for hypertension susceptibility loci in populations of Chinese and Japanese origins. Am J Hypertens 2003; 16:158-162.
54. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287:1680-1689.
55. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16:834-839.